179 related articles for article (PubMed ID: 30503387)
1. Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes.
Hassan M; Ulezko Antonova A; Li JM; Hosoba S; Rupji M; Kowalski J; Perricone AJ; Jaye DL; Marsh H; Yellin M; Devine S; Waller EK
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1075-1084. PubMed ID: 30503387
[TBL] [Abstract][Full Text] [Related]
2. Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation.
Darlak KA; Wang Y; Li JM; Harris WA; Owens LM; Waller EK
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1331-9. PubMed ID: 23810844
[TBL] [Abstract][Full Text] [Related]
3. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.
Waller EK; Logan BR; Harris WA; Devine SM; Porter DL; Mineishi S; McCarty JM; Gonzalez CE; Spitzer TR; Krijanovski OI; Linenberger ML; Woolfrey A; Howard A; Wu J; Confer DL; Anasetti C
J Clin Oncol; 2014 Aug; 32(22):2365-72. PubMed ID: 24982459
[TBL] [Abstract][Full Text] [Related]
4. Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression.
Zhu J; Wang Y; Li J; Das PK; Zhang H; Passang T; Li JM; Nagy T; Gandhi K; Ravindranathan S; Giver CR; Hassan M; Li Y; Antonova AU; Wang S; Roback JD; Waller EK
Blood; 2022 Sep; 140(12):1431-1447. PubMed ID: 35443019
[TBL] [Abstract][Full Text] [Related]
5. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
7. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
8. Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow.
Khanna A; Antonysamy MA; Subbotin VM; Steptoe RJ; Li W; Rudert WA; Thomson AW
Transpl Immunol; 1998 Dec; 6(4):225-34. PubMed ID: 10342736
[TBL] [Abstract][Full Text] [Related]
9. Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.
Capitini CM; Nasholm NM; Chien CD; Larabee SM; Qin H; Song YK; Klover PJ; Hennighausen L; Khan J; Fry TJ
Blood; 2014 Sep; 124(12):1976-86. PubMed ID: 25079358
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation.
Waller EK; Logan BR; Fei M; Lee SJ; Confer D; Howard A; Chandrakasan S; Anasetti C; Fernando SM; Giver CR
Blood Adv; 2019 Aug; 3(15):2250-2263. PubMed ID: 31345792
[TBL] [Abstract][Full Text] [Related]
11. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
12. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
[TBL] [Abstract][Full Text] [Related]
13. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
14. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
Li JM; Giver CR; Waller EK
Exp Hematol; 2006 Jul; 34(7):895-904. PubMed ID: 16797417
[TBL] [Abstract][Full Text] [Related]
15. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease.
Teshima T; Reddy P; Lowler KP; KuKuruga MA; Liu C; Cooke KR; Ferrara JL
Blood; 2002 Mar; 99(5):1825-32. PubMed ID: 11861301
[TBL] [Abstract][Full Text] [Related]
16. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
17. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non-depleted syngeneic bone marrow transplants.
Blazar BR; Aukerman SL; Vallera DA
Blood; 1992 Mar; 79(6):1636-42. PubMed ID: 1547353
[TBL] [Abstract][Full Text] [Related]
19. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
